替格瑞洛与氯吡格雷在颅内支架或血流导向装置治疗未破裂脑动脉瘤双联抗血小板方案中的比较:单中心队列研究
单中心队列研究回顾2003年11月至2019年2月201例未破裂脑动脉瘤患者(233个动脉瘤,236次手术),比较阿司匹林联合氯吡格雷(121例140个动脉瘤)与阿司匹林联合替格瑞洛(80例93个动脉瘤)在支架辅助栓塞或血流导向治疗中的疗效与安全性;90天主要结局(任何卒中及死亡复合终点)氯吡格雷组9.9% vs 替格瑞洛组8.6%(P=.822),结论提示替格瑞洛似乎与氯吡格雷同样有效且安全。
要点
- 90天主要复合终点(任何卒中及死亡)氯吡格雷组9.9% vs 替格瑞洛组8.6%,P=.822,两组无显著差异。
- 90天缺血性卒中氯吡格雷组7.0% vs 替格瑞洛组7.5%(P>.999),致残性卒中2.8% vs 4.3%(P=.716)。
- 90天任何出血氯吡格雷组9.2% vs 替格瑞洛组6.5%(P=.479),死亡2.1% vs 1.1%(P>.999)。
核心结论
- 在未破裂脑动脉瘤支架辅助栓塞或血流导向治疗中,替格瑞洛似乎与氯吡格雷同样有效且安全。
研究设计与样本
- 单中心回顾性队列研究,2003年11月至2019年2月纳入201例患者(平均年龄57.5岁,女性156例)共233个未破裂动脉瘤,行236次手术(支架辅助栓塞101次、血流导向135次),比较阿司匹林联合氯吡格雷组(121例140个动脉瘤)与阿司匹林联合替格瑞洛组(80例93个动脉瘤)的临床与影像资料。
诊断标准与关键数值
- 90天主要结局为任何卒中及死亡的复合终点:氯吡格雷组9.9% vs 替格瑞洛组8.6%(P=.822)。
- 90天缺血性卒中:氯吡格雷组10例(7.0%) vs 替格瑞洛组7例(7.5%)(P>.999)。
- 90天致残性卒中:氯吡格雷组4例(2.8%) vs 替格瑞洛组4例(4.3%)(P=.716)。
- 90天死亡:氯吡格雷组3例(2.1%) vs 替格瑞洛组1例(1.1%)(P>.999)。
- 90天任何出血:氯吡格雷组13例(9.2%) vs 替格瑞洛组6例(6.5%)(P=.479)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. This study evaluated the efficacy and safety of ticagrelor versus clopidogrel for stent-assisted coiling or flow-diversion treatment in patients with unruptured cerebral aneurysms.
MATERIALS AND METHODS: From November 2003 to February 2019, two hundred one patients (mean age, 57.5 years; 156 women) with 233 unruptured aneurysms underwent stent-assisted coiling or flow-diversion treatment. All patients received antiplatelet therapy of aspirin plus clopidogrel (clopidogrel group, 121 patients with 140 aneurysms) or aspirin plus ticagrelor (ticagrelor group, 80 patients with 93 aneurysms). The clinical and radiologic data in each group were retrospectively reviewed and compared.
RESULTS: Two hundred thirty-six procedures were performed, including stent-assisted coiling (n = 101) and flow diversion (n = 135). At 90 days, the primary outcome-a composite of any stroke and death-occurred in 9.9% of the clopidogrel group and 8.6% of the ticagrelor group (P = .822). Ischemic stroke occurred in 10 (7.0%) of the clopidogrel group and 7 (7.5%) of the ticagrelor group (P > .999). Disabling stroke occurred in 4 (2.8%) in the clopidogrel group and in 4 (4.3%) in the ticagrelor group (P = .716). Ninety-day death occurred in 3 (2.1%) in the clopidogrel group and 1 (1.1%) in the ticagrelor group (P > .999). Any bleeding at 90 days occurred in 13 (9.2%) in the clopidogrel group and 6 (6.5%) in the ticagrelor group (P = .479).
CONCLUSIONS: Ticagrelor appears to be as effective and safe as clopidogrel in stent-assisted coiling or flow-diversion treatment for unruptured cerebral aneurysms.
引用
- Park KY, Ozaki T, Kostynskyy A, et al. Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study. AJNR Am J Neuroradiol. 2021. PMID: 34244132. doi:10.3174/ajnr.A7216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。